CoChat

Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK

Open access

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Abstract

Bevacizumab is an anti-vascular endothelial growth factor monoclonal antibody that may prolong survival in ovarian and cervical cancer when given in combination with chemotherapy. It works by blocking the signalling pathways that are required for tumour angiogenesis, potentially limiting the cancer's ability to grow and spread. Hypertension is a known side effect of all angiogenesis inhibitors and could lead to interruption or premature discontinuation of effective anti-cancer treatment. Hypertension may also act as a barrier to the initiation of such treatment. In this review, we aim to present clear and practical recommendations on the management of blood pressure in ovarian and cervical cancer patients before, during and after bevacizumab treatment. This guidance covers considerations before initiating bevacizumab therapy and recommendations on the management of patients who develop hypertension, or who experience worsening of pre-existing hypertension, during bevacizumab treatment, and once the course of bevacizumab has been completed. These recommendations were developed collaboratively by a group of clinicians, comprising cardiologists, oncologists, a general practitioner and specialist oncology nurses, with expertise and practical experience in either oncology or hypertension. The aim of these recommendations is to support oncologists with hypertension assessment and management to facilitate starting or continuing bevacizumab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-019-0481-y

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Management of hypertension before and during bevacizumab therapy. aABPM/HBPM recorded over at least 4 consecutive days. bIf there is a marked difference between clinic BP and ABPM/HBPM (i.e., >20/10 mmHg), the latter should be repeated with a treatment target of <150/95 mmHg. ABPM ambulatory blood pressure monitoring, BP blood pressure, HBPM home blood pressure monitoring, n/a not applicable, NICE National Institute for Health and Care Excellence
Fig. 1 Management of hypertension before and during bevacizumab therapy. aABPM/HBPM recorded over at least 4 consecutive days. bIf there is a marked difference between clinic BP and ABPM/HBPM (i.e., >20/10 mmHg), the latter should be repeated with a treatment target of <150/95 mmHg. ABPM ambulatory blood pressure monitoring, BP blood pressure, HBPM home blood pressure monitoring, n/a not applicable, NICE National Institute for Health and Care ExcellenceCC BY · PubMed Central
Fig. 2 Treatment algorithm for antihypertensive-naive patients.a Note: this algorithm is not appropriate for patients with significant pre-existing cardiovascular disease. aIf patient is already on antihypertensive treatment, manage in accordance with NICE hypertension guidelines.47,50 ACE angiotensin-converting enzyme, ARB angiotensin II receptor blocker, K+ potassium, NICE National Institute for Health and Care Excellence
Fig. 2 Treatment algorithm for antihypertensive-naive patients.a Note: this algorithm is not appropriate for patients with significant pre-existing cardiovascular disease. aIf patient is already on antihypertensive treatment, manage in accordance with NICE hypertension guidelines.47,50 ACE angiotensin-converting enzyme, ARB angiotensin II receptor blocker, K+ potassium, NICE National Institute for Health and Care ExcellenceCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Cited by

See all 52

Metadata

Authors
Plummer, C., Michael, A., Shaikh, G., Stewart, M., Buckley, L., Miles, T., Ograbek, A., & McCormack, T.
Affiliations
  • Freeman Hospital (GB)
  • Royal Surrey County Hospital (GB)
  • James Cook University Hospital (GB)
  • Hull University Teaching Hospitals NHS Trust (GB)
  • Royal United Hospital Bath NHS Trust (GB)
  • Roche (United Kingdom) (GB)
  • Hull York Medical School (GB)
Corresponding author
Plummer, Chris
Venue
British Journal of Cancer
Published
2019-06-11
Volume
121
Issue
2
Pages
109-116
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2951382000
Cited by
52
References
69
Citations by year
2026: 3 · 2025: 7 · 2024: 6 · 2023: 9 · 2022: 7 · 2021: 12 · 2020: 6 · 2019: 2
FWCI
1.22
Type
journal article
Language
en
Open access
Licence
Locations
  • British Journal of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
Keywords
hypertension, bevacizumab, ovarian cancer, cervical cancer, anti-angiogenic therapy, blood pressure control, treatment discontinuation, pre-existing hypertension
MeSH terms
Bevacizumab, Uterine Cervical Neoplasms, Clinical Trials as Topic, Female, Humans, Hypertension, Ovarian Neoplasms, Angiogenesis Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. https://app.cochat.ai/papers/10.1038/s41416-019-0481-y
The paper
Plummer, C., Michael, A., Shaikh, G., Stewart, M., Buckley, L., Miles, T., Ograbek, A., & McCormack, T. (2019). Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. British Journal of Cancer. https://doi.org/10.1038/s41416-019-0481-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.